{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Chicago&page=22&state=Illinois",
    "query": {
      "state": "Illinois",
      "city": "Chicago",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 17813,
    "total_pages": 1782,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Chicago&page=23&state=Illinois&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Chicago&page=21&state=Illinois&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T18:36:46.048Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03245242",
      "title": "Pediatric Urology Recovery After Surgery Endeavor (PURSUE)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Urologic Surgical Procedures",
        "Urinary Bladder, Neurogenic",
        "Urinary Bladder Diseases"
      ],
      "interventions": [
        {
          "name": "Enhanced Recovery after Surgery",
          "type": "OTHER"
        },
        {
          "name": "Historical usual surgical care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "4 Years to 25 Years"
      },
      "enrollment_count": 85,
      "start_date": "2017-04-01",
      "completion_date": "2026-10-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-26",
      "last_synced_at": "2026-11-07T18:36:46.048Z",
      "location_count": 7,
      "location_summary": "Aurora, Colorado • Chicago, Illinois • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03245242"
    },
    {
      "nct_id": "NCT00000969",
      "title": "A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Zalcitabine",
          "type": "DRUG"
        },
        {
          "name": "Didanosine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 400,
      "start_date": null,
      "completion_date": "1992-09",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-11-07T18:36:46.048Z",
      "location_count": 16,
      "location_summary": "San Francisco, California • Denver, Colorado • New Haven, Connecticut + 11 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000969"
    },
    {
      "nct_id": "NCT05828069",
      "title": "A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Langerhans Cell Histiocytosis",
        "Refractory Langerhans Cell Histiocytosis"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "FDG-Positron Emission Tomography and Computed Tomography Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Lumbar Puncture",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Tovorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "180 Days",
        "maximum_age": "22 Years",
        "sex": "ALL",
        "summary": "180 Days to 22 Years"
      },
      "enrollment_count": 48,
      "start_date": "2024-03-28",
      "completion_date": "2028-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-11-07T18:36:46.048Z",
      "location_count": 108,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 85 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05828069"
    },
    {
      "nct_id": "NCT02160041",
      "title": "BGJ398 for Patients With Tumors With FGFR Genetic Alterations",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Hematologic Malignancies"
      ],
      "interventions": [
        {
          "name": "BGJ398",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2014-07-24",
      "completion_date": "2018-04-30",
      "has_results": true,
      "last_update_posted_date": "2019-06-18",
      "last_synced_at": "2026-11-07T18:36:46.048Z",
      "location_count": 56,
      "location_summary": "Birmingham, Alabama • Oceanside, California • San Francisco, California + 49 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Greenwood Village",
          "state": "Colorado"
        },
        {
          "city": "Norwalk",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02160041"
    },
    {
      "nct_id": "NCT00413205",
      "title": "TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Emphysema"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "RAR Gamma",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "44 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "44 Years and older"
      },
      "enrollment_count": 491,
      "start_date": "2007-01",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-11-07T18:36:46.048Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00413205"
    },
    {
      "nct_id": "NCT02163356",
      "title": "Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Neuroblastoma",
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "Fenretinide/LXS Oral Powder",
          "type": "DRUG"
        },
        {
          "name": "Ketoconazole",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "South Plains Oncology Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 4,
      "start_date": "2014-05",
      "completion_date": "2018-05",
      "has_results": false,
      "last_update_posted_date": "2022-03-31",
      "last_synced_at": "2026-11-07T18:36:46.048Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Dallas, Texas • Fort Worth, Texas + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02163356"
    },
    {
      "nct_id": "NCT00096356",
      "title": "Coenzyme Q10 in Relieving Treatment-Related Fatigue in Women With Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Fatigue"
      ],
      "interventions": [
        {
          "name": "CoQ10 & Vitamin E",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo & Vitamin E",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 236,
      "start_date": "2004-08-27",
      "completion_date": "2009-08-31",
      "has_results": true,
      "last_update_posted_date": "2021-09-29",
      "last_synced_at": "2026-11-07T18:36:46.048Z",
      "location_count": 31,
      "location_summary": "Phoenix, Arizona • Santa Rosa, California • Newark, Delaware + 24 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00096356"
    },
    {
      "nct_id": "NCT01028222",
      "title": "A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Nilotinib",
          "type": "DRUG"
        },
        {
          "name": "DTIC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2010-06",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2015-12-30",
      "last_synced_at": "2026-11-07T18:36:46.048Z",
      "location_count": 14,
      "location_summary": "Duarte, California • La Jolla, California • Los Angeles, California + 11 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01028222"
    },
    {
      "nct_id": "NCT05686551",
      "title": "GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Huntington Disease"
      ],
      "interventions": [
        {
          "name": "Tominersen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "25 Years to 50 Years"
      },
      "enrollment_count": 301,
      "start_date": "2023-02-03",
      "completion_date": "2026-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-11-07T18:36:46.048Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05686551"
    },
    {
      "nct_id": "NCT06620302",
      "title": "Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Childhood Fibrolamellar Carcinoma",
        "Recurrent Childhood Fibrolamellar Carcinoma",
        "Recurrent Childhood Malignant Solid Neoplasm",
        "Recurrent Fibrolamellar Carcinoma",
        "Recurrent Malignant Solid Neoplasm",
        "Refractory Childhood Fibrolamellar Carcinoma",
        "Refractory Childhood Malignant Solid Neoplasm",
        "Refractory Fibrolamellar Carcinoma",
        "Refractory Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Bcl-XL Proteolysis Targeting Chimera DT2216",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "1 Year to 39 Years"
      },
      "enrollment_count": 81,
      "start_date": "2025-06-12",
      "completion_date": "2031-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-11-07T18:36:46.048Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06620302"
    }
  ]
}